| 24.835 0.115 (0.47%) | 05-28 11:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.68 | 1-year : | 38.17 |
| Resists | First : | 27.97 | Second : | 32.68 |
| Pivot price | 24.02 |
|||
| Supports | First : | 22.03 | Second : | 18.36 |
| MAs | MA(5) : | 25.4  |
MA(20) : | 23.01 |
| MA(100) : | 20.05 |
MA(250) : | 17.46 |
|
| MACD | MACD : | 1.1 |
Signal : | 1 |
| %K %D | K(14,3) : | 70.7 |
D(3) : | 74.2 |
| RSI | RSI(14): 55.9 |
|||
| 52-week | High : | 27.97 | Low : | 12.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PLSE ] has closed below upper band by 41.7%. Bollinger Bands are 38% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.96 - 26.1 | 26.1 - 26.21 |
| Low: | 24.35 - 24.51 | 24.51 - 24.63 |
| Close: | 24.47 - 24.73 | 24.73 - 24.94 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Wed, 27 May 2026
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Yahoo Finance
Wed, 27 May 2026
Here's why Pulse Biosciences, Inc (PLSE) is a great momentum stock to buy - MSN
Thu, 21 May 2026
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Surge - Sahm
Fri, 15 May 2026
Director Robert Duggan buys 660K Pulse Biosciences (PLSE) shares - Stock Titan
Wed, 13 May 2026
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Tue, 12 May 2026
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 1.766e+007 (%) |
| Held by Institutions | 73.3 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.64e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 775.5 % |
| Return on Equity (ttm) | -45.1 % |
| Qtrly Rev. Growth | 751000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -49.53 |
| EBITDA (p.s.) | -96932.5 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.51 |
| Price to Cash Flow | 34.06 |
| Dividend | 0 |
| Forward Dividend | 2.92e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|